Literature DB >> 23071240

Methods in comparative effectiveness research.

Katrina Armstrong1.   

Abstract

Comparative effectiveness research (CER) seeks to assist consumers, clinicians, purchasers, and policy makers to make informed decisions to improve health care at both the individual and population levels. CER includes evidence generation and evidence synthesis. Randomized controlled trials are central to CER because of the lack of selection bias, with the recent development of adaptive and pragmatic trials increasing their relevance to real-world decision making. Observational studies comprise a growing proportion of CER because of their efficiency, generalizability to clinical practice, and ability to examine differences in effectiveness across patient subgroups. Concerns about selection bias in observational studies can be mitigated by measuring potential confounders and analytic approaches, including multivariable regression, propensity score analysis, and instrumental variable analysis. Evidence synthesis methods include systematic reviews and decision models. Systematic reviews are a major component of evidence-based medicine and can be adapted to CER by broadening the types of studies included and examining the full range of benefits and harms of alternative interventions. Decision models are particularly suited to CER, because they make quantitative estimates of expected outcomes based on data from a range of sources. These estimates can be tailored to patient characteristics and can include economic outcomes to assess cost effectiveness. The choice of method for CER is driven by the relative weight placed on concerns about selection bias and generalizability, as well as pragmatic concerns related to data availability and timing. Value of information methods can identify priority areas for investigation and inform research methods.

Entities:  

Mesh:

Year:  2012        PMID: 23071240      PMCID: PMC3504326          DOI: 10.1200/JCO.2012.42.2659

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  57 in total

1.  I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.

Authors:  A D Barker; C C Sigman; G J Kelloff; N M Hylton; D A Berry; L J Esserman
Journal:  Clin Pharmacol Ther       Date:  2009-05-13       Impact factor: 6.875

2.  A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.

Authors:  Kevin E Thorpe; Merrick Zwarenstein; Andrew D Oxman; Shaun Treweek; Curt D Furberg; Douglas G Altman; Sean Tunis; Eduardo Bergel; Ian Harvey; David J Magid; Kalipso Chalkidou
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

3.  STREPTOMYCIN treatment of pulmonary tuberculosis.

Authors: 
Journal:  Br Med J       Date:  1948-10-30

4.  Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change.

Authors:  Bryan R Luce; Judith M Kramer; Steven N Goodman; Jason T Connor; Sean Tunis; Danielle Whicher; J Sanford Schwartz
Journal:  Ann Intern Med       Date:  2009-06-30       Impact factor: 25.391

5.  The triple aim: care, health, and cost.

Authors:  Donald M Berwick; Thomas W Nolan; John Whittington
Journal:  Health Aff (Millwood)       Date:  2008 May-Jun       Impact factor: 6.301

6.  Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients.

Authors:  Anirban Basu; James J Heckman; Salvador Navarro-Lozano; Sergio Urzua
Journal:  Health Econ       Date:  2007-11       Impact factor: 3.046

7.  Survival following primary androgen deprivation therapy among men with localized prostate cancer.

Authors:  Grace L Lu-Yao; Peter C Albertsen; Dirk F Moore; Weichung Shih; Yong Lin; Robert S DiPaola; Siu-Long Yao
Journal:  JAMA       Date:  2008-07-09       Impact factor: 56.272

8.  Adjuvant chemotherapy in older women with early-stage breast cancer.

Authors:  Hyman B Muss; Donald A Berry; Constance T Cirrincione; Maria Theodoulou; Ann M Mauer; Alice B Kornblith; Ann H Partridge; Lynn G Dressler; Harvey J Cohen; Heather P Becker; Patricia A Kartcheske; Judith D Wheeler; Edith A Perez; Antonio C Wolff; Julie R Gralow; Harold J Burstein; Ahmad A Mahmood; Gustav Magrinat; Gutav Magrinat; Barbara A Parker; Ronald D Hart; Debjani Grenier; Larry Norton; Clifford A Hudis; Eric P Winer
Journal:  N Engl J Med       Date:  2009-05-14       Impact factor: 91.245

9.  Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.

Authors:  Peter F Thall; Christopher Logothetis; Lance C Pagliaro; Sijin Wen; Melissa A Brown; Dallas Williams; Randall E Millikan
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

10.  The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP Working Group.

Authors:  Steven M Teutsch; Linda A Bradley; Glenn E Palomaki; James E Haddow; Margaret Piper; Ned Calonge; W David Dotson; Michael P Douglas; Alfred O Berg
Journal:  Genet Med       Date:  2009-01       Impact factor: 8.822

View more
  27 in total

1.  Level of hospital care and outcome of gastric cancer: a population-based evaluation of the Munich Cancer Registry.

Authors:  Anne Schlesinger-Raab; André L Mihaljevic; Silvia Egert; Rebecca T Emeny; Karl-Walter Jauch; Jörg Kleeff; Alexander Novotny; Natascha C Nüssler; Miriam Rottmann; Wolfgang Schepp; Wolfgang Schmitt; Gabriele Schubert-Fritschle; Bernhard Weber; Christoph Schuhmacher; Jutta Engel
Journal:  J Cancer Res Clin Oncol       Date:  2014-03-15       Impact factor: 4.553

2.  Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.

Authors:  Jason D Wright; Cande V Ananth; Jennifer Tsui; Sherry A Glied; William M Burke; Yu-Shiang Lu; Alfred I Neugut; Thomas J Herzog; Dawn L Hershman
Journal:  Cancer       Date:  2014-01-17       Impact factor: 6.860

Review 3.  Conceptual and methodological issues in research on mindfulness and meditation.

Authors:  Richard J Davidson; Alfred W Kaszniak
Journal:  Am Psychol       Date:  2015-10

4.  Harms, benefits, and the nature of interventions in pragmatic clinical trials.

Authors:  Joseph Ali; Joseph E Andrews; Carol P Somkin; C Egla Rabinovich
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

Review 5.  Head-to-head trials in inflammatory bowel disease: past, present and future.

Authors:  Lieven Pouillon; Simon Travis; Peter Bossuyt; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-04-17       Impact factor: 46.802

6.  Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.

Authors:  Prajakta P Masurkar; Satabdi Chatterjee; Jeffrey T Sherer; Hua Chen; Michael L Johnson; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2022-06-06       Impact factor: 4.271

7.  Bisphosphonates and mortality in women with CKD and the presence or absence of cardiovascular disease.

Authors:  Robert M Perkins; H Lester Kirchner; Kunihiro Matsushita; Ion D Bucaloiu; Evan Norfolk; James E Hartle
Journal:  Clin J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 8.237

8.  Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).

Authors:  Elizabeth B Lamont; Menggang Yu; Yulei He; Leonard Saltz; Hyman Muss; Alan M Zaslavsky
Journal:  J Geriatr Oncol       Date:  2014-03-01       Impact factor: 3.599

9.  Distinguishing Selection Bias and Confounding Bias in Comparative Effectiveness Research.

Authors:  Sebastien Haneuse
Journal:  Med Care       Date:  2016-04       Impact factor: 2.983

Review 10.  Comparing the Effectiveness of Methods to Measure Oxygen in Tissues for Prognosis and Treatment of Cancer.

Authors:  Ann Barry Flood; Victoria A Satinsky; Harold M Swartz
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.